MedTrace Logo

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

NCT04540692 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 444

Last updated 2024-06-04

No results posted yet for this study

Summary

Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.

Conditions

Interventions

DRUG

Docetaxel or Paclitaxel

Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks

DRUG

Cyclophosphamide + Doxorrubicin

Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles

Sponsors & Collaborators

  • Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)

    collaborator UNKNOWN

  • Latin American Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • José Bines · Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2026-04-30
Completion
2030-08-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04540692 on ClinicalTrials.gov